Equillium, a biotech company, granted 800,000 nonstatutory stock options to two new employees as inducement awards under its 2024 Inducement Plan. The options, priced at $2.08 each (the stock's closing price on May 1, 2026), will vest over four years, encouraging employee retention. This move complies with Nasdaq Listing Rule 5635(c)(4) and aims to attract key talent to support Equillium's development of therapies for autoimmune and inflammatory disorders. The company’s lead drug candidate, EQ504, targets diseases like ulcerative colitis and inflammatory lung conditions.
Crédit Agricole S.A. disclosed its voting rights status as of June 30, 2026, reporting a total of 3,025,902,350 shares and an almost equal number of theoretical voting rights. The exercisable voting rights, accounting for shares held in treasury and ...
The Sweden flu diagnostic and treatment market is projected to grow from USD 172.1 million in 2026 to USD 210.3 million by 2031, at a 4.1% CAGR. Growth is driven by high influenza burden among seniors, increased demand for rapid molecular diagnostics...
In Q2 2026, NIU Technologies sold 434,687 electric mobility units, marking a 25% year-over-year increase in China with 402,202 units sold. Growth was fueled by strong demand for core and new smart electric models, including the NX 2026 long-range mot...
HSBC Continental Europe announced that no stabilisation activities were performed in relation to the EUR 750 million bond offering by Assicurazioni Generali S.p.A., which carries a 4.406% coupon due June 2037. This means the stabilisation manager did...
RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to acquire David Brown Defence, a UK company specializing in high-precision gearboxes for naval and land defense. This acquisition will strengthen RENK's naval sector por...
